Evidence for the implication of phosphoinositol signal transduction in mu-opioid inhibition of DNA synthesis.
An opioid receptor agonist, [D-Ala2,Me-Phe4,Glyol5]enkephalin (DAMGE), decreased [3H]thymidine incorporation into DNA of fetal rat brain cell aggregates. This action proved to depend on the dose of this enkephalin analog and the interval the aggregates were maintained in culture. The opioid antagonist naltrexone and the mu-specific antagonist cyclic D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide (CTOP) reversed the DAMGE effect, arguing for a receptor-mediated mechanism. The mu-opioid nature of this receptor was further established by inhibiting DNA synthesis with the highly mu-selective agonist morphiceptin and blocking its action with CTOP. Several other opioids, pertussis toxin, and LiCl also diminished DNA synthesis, whereas cholera toxin elicited a modest increase. Naltrexone completely reversed the inhibition elicited by the combination of DAMGE and low doses of LiCl but not by that of high levels of LiCl alone. The enkephalin analog also reduced basal [3H]inositol trisphosphate and glutamate-stimulated [3H]inositol monophosphate and [3H]inositol bisphosphate accumulation in the aggregates. These DAMGE effects were reversed by naltrexone and were temporally correlated with the inhibition of DNA synthesis. A selective protein kinase C inhibitor, chelerythrine, also inhibited thymidine incorporation dose-dependently. The effect of DAMGE was not additive in the presence of chelerythrine but appeared to be consistent with their actions being mediated via a common signaling pathway. These results suggest the involvement of the phosphoinositol signal transduction system in the modulation of thymidine incorporation into DNA by DAMGE.
Barg
J
J
E. A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, Missouri 63104-1079.
Belcheva
M M
MM
Coscia
C J
CJ
D000818:Animals; D002478:Cells, Cultured; D002712:Chlorides / Q000494:pharmacology; D002772:Cholera Toxin / Q000494:pharmacology; D004247:DNA / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism; D007295:Inositol Phosphates / Q000502:physiology*; D008094:Lithium / Q000494:pharmacology; D018021:Lithium Chloride; D037342:Pertussis Toxin; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011957:Receptors, Opioid / Q000378:metabolism / Q000502:physiology*; D017450:Receptors, Opioid, mu; D015398:Signal Transduction / Q000502:physiology*; D013936:Thymidine / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D002712:Chlorides; D004745:Enkephalins; D007295:Inositol Phosphates; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D010566:Virulence Factors, Bordetella; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004247:DNA; D002772:Cholera Toxin; D008094:Lithium; D037342:Pertussis Toxin; D011493:Protein Kinase C; D019204:GTP-Binding Proteins; D018021:Lithium Chloride; D013936:Thymidine